NasdaqGM:KODBiotechs
Why Kodiak Sciences (KOD) Is Down 15.4% After Zenkuda’s Phase III GLOW2 Win And Accelerated Filing
Kodiak Sciences recently reported that its Phase III GLOW2 trial of Zenkuda for diabetic retinopathy met primary and key secondary endpoints with strong efficacy, and the company is also advancing multiple late-stage ophthalmology programs while maintaining a solid, debt-free balance sheet.
This combination of positive late-stage data and an accelerated regulatory submission plan highlights how central Zenkuda has become to Kodiak’s overall pipeline story.
Next, we’ll examine how Zenkuda’s...